Louisiana Medicaid’s subscription-based payment model (SBPM) for hepatitis C virus (HCV) medications led to a 534% relative increase in HCV prescription fills. After Louisiana launched its SBPM with Asegua Therapeutics in 2019, the number of HCV prescription fills for the authorized generic of Epclusa translates to an estimated increase of 173.5 quarterly prescription fills per 100,000 Medicaid enrollees. SBPMs are models in which states contract exclusively with a single manufacturer to supply prescriptions at a reduced price, and Louisiana was one of the first two states to implement SBPMs in 2019. Louisiana used a two-part . . .
News Report |